Abstract:Objective:To explore the efficacy and influencing factors of radiofrequency ablation (RFA) in the treatment of colorectal cancer liver metastases (CRLM).Methods:The clinical and imaging data of 281 patients (477 intrahepatic metastatic tumors) who received percutaneous RFA treatment in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine from December 2009 to December 2020 were retrospectively analyzed. Factors that may affect the efficacy of RFA were recorded, including carcinoembryonic antigen (CEA), differentiation, extrahepatic metastasis, tumor location and size, complications and other information. Patients were followed up through hospital admissions, telephone, etc. The primary endpoints were overall survival (OS) and local tumor progression-free survival (LTPFS). Univariate and multivariate logistic regression models were used to identify predictors of residual tumor. Univariate and multivariate Cox proportional hazards regression were used to identify the influencing factors of LTPFS and OS. The median LTPFS and OS were estimated by the Kaplan-Meier curve and compared by the log-rank test.Results:After RFA, 68 (14.3%) tumor residues were observed. Multivariate logistic regression showed that the risk factors for residual tumor were size ≥20 mm, high-risk and perivascular location, and minimal ablative margin<5 mm. During the follow-up period, the main complication rate was 4.3% (12/281) and the fatality rate was 31.3% (88/281). At the same time, local tumor progression was found in 167 (35.0%) lesions post-RFA. The median time of LTPFS and OS estimated by the Kaplan Meier method were 35.0 (95%CI 26.53-43.48) and 44.0 (95%CI 29.70-58.30) months, respectively. The cumulative proportion of LTPFS and OS were 37.2% and 40.4% respectively in the 5th year. Multivariate Cox proportional hazard regression showed that CEA≥30 ng/ml, tumor size ≥20 mm, and minimal ablative margin<5 mm were risk factors for LTPFS; extrahepatic metastasis, tumor burden>30 mm, and lesion with minimal ablative margin<5 mm were independent risk factors for OS; re-intervention was an independent protective factor for OS.Conclusions:Adequate ablative margin and less tumor burden were beneficial to local tumor control and long-term survival of patients in the RFA treatment; the existence of extrahepatic metastasis was an important risk factor for OS, and re-interventional therapy was beneficial to extend OS.

Current Progression of Radiofrequency Ablation (RFA) in Clinical Application of Lung Cancer Therapy

Radiofrequency ablation for stage <IIB non-small cell lung cancer: Opportunities, challenges, and the road ahead

A Systematic Review of Radiofrequency Ablation for Lung Tumors

Radiofrequency Ablation of Advanced Lung Tumors: Imaging Features, Local Control, and Follow-Up Protocol.

Clinical observation of radiofrequency ablation for treating patients with lung cancer

Radiofrequency ablation: mechanisms and clinical applications

Radiofrequency ablation for the treatment of advanced non-small-cell lung cancer: a meta-analysis

CT-guided Percutaneous Minimally Invasive Radiofrequency Ablation for the Relief of Cancer Related Pain from Metastatic Non-Small Cell Lung Cancer Patients: a Retrospective Study.

Clinical application of radiofrequency ablation in gastric cancer liver metastasis

A prospective clinical trial of radiofrequency ablation for pulmonary metastases.

Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α

The Value of Cone-Beam CT-guided Radiofrequency Ablation in the Treatment of Pulmonary Malignancies (≤3 Cm).

Radiofrequency Ablation-Combined Multimodel Therapies for Hepatocellular Carcinoma: Current Status.

The Progress of Radiofrequency Ablation for the Treatment of Liver Cancer

[Effectiveness of radiofrequency ablation of lung tumours]

Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases

Clinical Effect of Percutaneous Radiofrequency Ablation for Residual Lung Metastases from Breast Cancer After Systemic Chemotherapy

Radiofrequency Ablation in the Treatment of Liver Cancer in the Era of Minimally Invasive Surgery

Clinical short-term results of radiofrequency ablation in liver cancers.

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Percutaneous Radiofrequency Ablation Is an Effective Method for Local Control of Liver Metastases From Lung Cancer